Quarterly ResultAug 5, 2026, 09:14 AM
Royalty Pharma YTD Net Income $312.6M; Operating Cash Flow $1.45B
AI Summary
Royalty Pharma reported a net income attributable to the company of $312.6 million for the six months ended June 30, 2026, an increase from $271.5 million in the prior year. Basic earnings per share for the period rose to $0.71 from $0.63. The company also generated strong operating cash flows of $1.45 billion, significantly up from $960.1 million year-over-year, while Q2 net income attributable to Royalty Pharma plc decreased to $17.9 million.
Key Highlights
- Net income attributable to Royalty Pharma plc for YTD 2026 was $312.6M, up from $271.5M.
- Basic EPS for YTD 2026 was $0.71, compared to $0.63 in the prior year period.
- Net cash provided by operating activities for YTD 2026 increased to $1.45B from $960.1M.
- Acquisitions of financial royalty assets totaled $703.4M in YTD 2026.
- Q2 2026 net income attributable to Royalty Pharma plc was $17.9M, down from $32.2M.
- Share-based compensation expense for YTD 2026 was $229.6M, up from $91.7M.
- ASU 2025-07 adoption resulted in a $12.0M cumulative-effect adjustment to retained earnings.
Price Impact
More from RPRX